Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic acid [RNA] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection 
Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation) 
Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation 
Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination 
Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis       
    

NCT02788045_exc_T1
Condition
chronic hepatitis B
NCT02788045_exc_T2
Measurement
hepatitis B surface antigen test
NCT02788045_exc_T3
Condition
active hepatitis C
NCT02788045_exc_T4
Measurement
hepatitis C virus [HCV] Ab test
NCT02788045_exc_T5
Value
positive
NCT02788045_exc_T6
Measurement
HCV ribonucleic acid [RNA] PCR test
NCT02788045_exc_T7
Qualifier
active
NCT02788045_exc_T8
Condition
syphilis infection
NCT02788045_exc_T9
Condition
chlamydia
NCT02788045_exc_T10
Condition
gonorrhea
NCT02788045_exc_T11
Condition
trichomonas
NCT02788045_exc_T12
Qualifier
Active
NCT02788045_exc_T13
Condition
syphilis
NCT02788045_exc_T14
Measurement
serology
NCT02788045_exc_T15
Measurement
serology
NCT02788045_exc_T16
Value
positive
NCT02788045_exc_T19
Condition
treated infection
NCT02788045_exc_T20
Negation
unless
NCT02788045_exc_T21
Procedure
thyroidectomy
NCT02788045_exc_T22
Condition
thyroid disease
NCT02788045_exc_T23
Qualifier
active
NCT02788045_exc_T24
Drug
medication
NCT02788045_exc_T26
Temporal
during the last 12 months
NCT02788045_exc_T27
Drug
thyroid supplementation
NCT02788045_exc_T28
Qualifier
stable
NCT02788045_exc_T29
Condition
psychiatric illness
NCT02788045_exc_T30
Qualifier
major
NCT02788045_exc_T32
Condition
substance abuse
NCT02788045_exc_T33
Temporal
during the past 12 months
NCT02788045_exc_T34
Procedure
hospitalization
NCT02788045_exc_T35
Condition
work disability
NCT02788045_exc_T36
Scope
hospitalization or periods of work disability
NCT02788045_exc_T37
Scope
major psychiatric illness and/or substance abuse
NCT02788045_exc_T40
Drug
licensed vaccine
NCT02788045_exc_T41
Temporal
within 14 days prior
NCT02788045_exc_T42
Reference_point
the first dose of study vaccine/placebo
NCT02788045_exc_T43
Temporal
within 14 days after
NCT02788045_exc_T44
Reference_point
first study vaccination
NCT02788045_exc_T45
Drug
study vaccine
NCT02788045_exc_T46
Drug
placebo
NCT02788045_exc_T47
Procedure
study vaccination
NCT02788045_exc_T49
Temporal
within 14 days before or after
NCT02788045_exc_T50
Reference_point
second, third or fourth vaccination
NCT02788045_exc_T51
Drug
vaccination
NCT02788045_exc_T53
Scope
within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination
NCT02788045_exc_T54
Drug
HIV vaccine candidate
NCT02788045_exc_T55
Temporal
at any time
NCT02788045_exc_T56
Drug
other experimental vaccine(s)
NCT02788045_exc_T58
Temporal
within the last 12 months
NCT02788045_exc_T59
Qualifier
therapeutic
NCT02788045_exc_T60
Qualifier
prophylactic
NCT02788045_exc_T61
Scope
prophylactic or therapeutic
NCT02788045_exc_T62
Drug
experimental vaccine
NCT02788045_exc_T63
Drug
HIV vaccine
NCT02788045_exc_T64
Negation
except
NCT02788045_exc_T65
Temporal
more than 12 months ago
NCT02788045_exc_T17
Negation
not excluded